Bulk Pharmaceutical API Sources for BEPREVE

Bulk Pharmaceutical API Sources for BEPREVE

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-005-938-034
Amadis Chemical		A813441
MedChemexpress MCE		HY-A0015

Bepreve Bulk Active Pharmaceutical Ingredient (API) Sources

Last updated: February 19, 2026

This report analyzes the landscape of bulk Active Pharmaceutical Ingredient (API) suppliers for Bepreve (uticas®), a prescription ophthalmic solution used to treat itching associated with allergic conjunctivitis. The analysis focuses on identifying key manufacturers, their production capabilities, regulatory standing, and potential supply chain risks.

What is Bepreve API?

Bepreve API refers to the bulk, unformulated uticas® molecule, the pharmacologically active component of the Bepreve® ophthalmic solution. Uticas®, chemically known as 1-{[2-(4-Fluorophenyl)-2-oxoethyl]amino}-2-(3-hydroxyphenyl)ethanol, is a selective histamine H1 receptor antagonist. The API is the foundational material from which the final drug product is manufactured. Its quality, purity, and consistent supply are critical for the efficacy and safety of the Bepreve® ophthalmic solution.

Who Manufactures Bepreve API?

The manufacturing of Bepreve API is primarily concentrated among a limited number of specialized chemical synthesis companies. These entities are responsible for the multi-step chemical processes required to produce uticas® to pharmaceutical-grade specifications.

• Novartis AG (Original Innovator): As the originator of Bepreve®, Novartis AG would have developed and likely maintained internal or contracted manufacturing processes for the API during the drug's development and initial commercialization.
• Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs): Post-exclusivity or for broader market access, specialized CMOs and CDMOs with expertise in complex organic synthesis and handling ophthalmic APIs are likely candidates for Bepreve API production. These organizations operate under strict regulatory oversight.

Specific manufacturers are often not publicly disclosed due to competitive and intellectual property considerations. However, companies with established capabilities in small molecule API synthesis, particularly for ophthalmic or ophthalmic-like applications, are potential players. These might include:

• Lonza: A global leader in API manufacturing with extensive experience in complex chemical synthesis.
• Catalent Pharma Solutions: Offers integrated drug development and manufacturing services, including API production.
• Thermo Fisher Scientific (Patheon): A significant player in contract manufacturing for pharmaceuticals.
• WuXi AppTec: A prominent China-based CDMO with broad API manufacturing capabilities.
• Divi's Laboratories: An Indian API manufacturer known for its backward integration and large-scale production.

The selection of an API manufacturer is contingent upon several factors, including the manufacturer's ability to meet stringent quality standards (e.g., Good Manufacturing Practices - GMP), regulatory compliance history, production capacity, cost-effectiveness, and intellectual property protection agreements.

What are the Regulatory Requirements for Bepreve API?

The production and supply of Bepreve API are subject to rigorous regulatory oversight by health authorities worldwide. Compliance with these regulations is mandatory for API used in finished pharmaceutical products.

• Good Manufacturing Practices (GMP): API manufacturers must adhere to GMP guidelines, which ensure that products are consistently produced and controlled according to quality standards. These standards cover all aspects of production, from raw materials and premises to equipment and personnel training. Key GMP regulatory bodies include:
  • U.S. Food and Drug Administration (FDA): Requires adherence to 21 CFR Part 210 and 211.
  • European Medicines Agency (EMA): Governed by EudraLex Volume 4.
  • Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
  • Therapeutic Goods Administration (TGA) in Australia.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF is a submission to a regulatory agency that contains full information about the facilities, processes, or articles used in manufacturing, processing, packaging, and storing of human drugs. This allows the agency to review the API information in support of a drug product application without disclosing proprietary information to the drug product applicant.
  • U.S. DMFs: Filed with the FDA.
  • European EDMFs (European Drug Master Files): Filed with national competent authorities or through the Centralised Procedure.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides harmonized guidelines on quality, safety, and efficacy. Relevant ICH guidelines for API include:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
  • ICH Q11: Development and Manufacture of Drug Substances.
  • ICH Q3A/B/C/D: Impurities.
• Quality Agreements: A formal quality agreement between the API manufacturer and the finished drug product manufacturer is crucial. This document outlines the responsibilities of each party regarding quality control, change management, and regulatory compliance.

What are the Key Synthesis Routes and Impurity Profiles?

The synthesis of uticas® involves complex multi-step organic chemistry. While specific proprietary routes are confidential, general synthetic strategies for similar molecules involve:

1. Formation of a key intermediate: This often involves reactions such as Friedel-Crafts acylation to introduce the fluorophenyl ketone moiety.
2. Amine coupling: Subsequent reaction with an amino-alcohol precursor or formation of an epoxide followed by ring-opening with an amine.
3. Functional group manipulation: Steps like reduction, protection, and deprotection may be employed to achieve the final structure of uticas®.

Potential Impurity Types:

The impurity profile of an API is critical for drug safety. Impurities can arise from starting materials, reagents, by-products, intermediates, and degradation products. For uticas®, potential impurities could include:

• Related Substances: Structurally similar compounds arising from incomplete reactions or side reactions during synthesis. Examples might include unreacted starting materials, intermediates, or over-reacted products.
• Stereoisomers: Uticas® has a chiral center. The presence of unwanted stereoisomers (enantiomers or diastereomers) needs to be controlled and quantified.
• Residual Solvents: Solvents used in the synthesis and purification process, which must be controlled to acceptable limits as per ICH Q3C guidelines. Common solvents might include methanol, ethanol, isopropanol, ethyl acetate, toluene, and dichloromethane.
• Heavy Metals: Contaminants from reagents, equipment, or water sources. Limits are set by pharmacopeias (e.g., USP, EP).
• Degradation Products: Formed during storage or manufacturing of the API, potentially due to oxidation, hydrolysis, or photolysis.

The development and validation of analytical methods to detect and quantify these impurities are a regulatory requirement. These methods, such as High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Mass Spectrometry (MS), are integral to ensuring API quality.

What is the Market Landscape for Bepreve API?

The market for Bepreve API is influenced by several factors:

• Exclusivity and Patent Status: Bepreve® (uticas®) is an established product. The patent landscape for the molecule and its formulations will dictate the entry of generic manufacturers and, consequently, the demand for third-party API suppliers. Information regarding patent expiry dates for Bepreve® is crucial for projecting future API market dynamics.
• Global Demand: The prevalence of allergic conjunctivitis in various geographic regions drives the demand for Bepreve® and its API. Factors such as environmental allergens, pollen seasons, and population demographics play a role.
• Generic Competition: As patents expire, generic versions of Bepreve® can enter the market, increasing the number of drug product manufacturers requiring uticas® API. This typically leads to increased competition among API suppliers and potential price erosion.
• Supply Chain Resilience: The COVID-19 pandemic highlighted the importance of supply chain resilience. Pharmaceutical companies often seek to diversify their API sources to mitigate risks associated with single-supplier dependencies, geopolitical instability, or regional manufacturing disruptions.
• Manufacturing Costs and Geographic Concentration: API manufacturing costs can vary significantly by region. While historically, manufacturing has shifted to Asia (China, India), there is a growing trend towards reshoring or near-shoring to ensure quality control and reduce lead times.

Key Considerations for API Sourcing:

• Capacity and Scalability: Can the supplier reliably produce the required volumes of API, and can they scale up production to meet increased demand?
• Quality Assurance and Regulatory Compliance: Does the supplier have a robust quality management system and a strong track record with regulatory agencies?
• Cost-Effectiveness: Is the API priced competitively while maintaining quality standards?
• Lead Times and Delivery Reliability: Can the supplier deliver API on time to prevent drug product manufacturing delays?
• Intellectual Property Protection: For innovator companies, ensuring API suppliers do not infringe on existing patents is paramount. For generic companies, access to non-infringing manufacturing processes is key.

What are the Supply Chain Risks for Bepreve API?

Several risks can impact the consistent and reliable supply of Bepreve API:

• Regulatory Hurdles: Changes in regulatory requirements, failed inspections, or delays in DMF approvals can disrupt supply. Any non-compliance issues at an API manufacturing site can lead to production halts and import alerts.
• Geopolitical Instability: For API sourced from specific regions, geopolitical tensions, trade wars, or political instability can disrupt manufacturing and transportation.
• Raw Material Availability and Price Fluctuations: The synthesis of uticas® relies on specific chemical precursors. Disruptions in the supply of these raw materials or significant price increases can impact API production costs and availability.
• Manufacturing Site Issues: Unforeseen events at a manufacturing facility, such as equipment failures, natural disasters, or labor disputes, can lead to production downtime.
• Intellectual Property Disputes: Patent litigation or disputes over manufacturing processes can create uncertainty and potentially halt the supply of API.
• Quality Control Failures: A batch failure due to quality deviations can result in significant delays, product recalls, and reputational damage for both the API manufacturer and the drug product manufacturer.
• Logistics and Transportation Challenges: Delays in shipping, customs issues, or increased freight costs can impact the timely delivery of API.

Key Takeaways

• The bulk API for Bepreve (uticas®) is manufactured through complex organic synthesis, primarily by specialized CMOs/CDMOs, with Novartis AG as the innovator.
• API production is heavily regulated, requiring strict adherence to GMP and submission of Drug Master Files to health authorities like the FDA and EMA.
• Potential impurities include related substances, stereoisomers, residual solvents, and heavy metals, necessitating rigorous analytical control.
• The market landscape is influenced by patent expiry, generic competition, global demand for allergic conjunctivitis treatments, and the drive for supply chain resilience.
• Key supply chain risks include regulatory compliance issues, geopolitical factors, raw material availability, manufacturing site disruptions, and quality control failures.

FAQs

1. How can a pharmaceutical company identify potential Bepreve API suppliers? Pharmaceutical companies can identify potential suppliers through industry databases, trade shows, regulatory agency filings (e.g., DMFs), and by engaging with pharmaceutical sourcing consultants. Due diligence includes reviewing regulatory compliance history, manufacturing capabilities, and quality systems.

2. What is the typical lead time for securing a supply of Bepreve API from a new manufacturer? The lead time can vary significantly but typically ranges from 6 to 18 months. This includes supplier qualification, site audits, process validation, and initial production runs, alongside regulatory review if a new DMF is required.

3. Are there any specific environmental or sustainability considerations for Bepreve API manufacturing? API manufacturing, like all chemical synthesis, has environmental impacts. Manufacturers are increasingly expected to adopt green chemistry principles, optimize solvent use and recovery, manage waste streams responsibly, and reduce energy consumption. Regulatory agencies are also paying more attention to environmental compliance.

4. What impact does the patent status of Bepreve have on the API supply chain? The patent status directly affects the API supply chain. During patent protection, supply is typically controlled by the innovator or their designated manufacturers. Post-patent expiry, generic drug manufacturers can enter the market, leading to increased demand for API from multiple sources and potentially a more competitive pricing environment for API suppliers.

5. How are changes in the Bepreve formulation (e.g., new excipients) likely to affect API sourcing? Changes in the drug product formulation typically do not directly affect the sourcing of the bulk API itself, as the API's chemical identity and quality remain paramount. However, changes in formulation might impact the stability profile of the API during storage or its compatibility during the drug product manufacturing process, which could necessitate minor adjustments in API handling or packaging specifications agreed upon in quality agreements.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210 & 211 - Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs; General. Retrieved from [FDA Website] (Actual URL would require specific search or access to FDA regulations). [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4. Good Manufacturing Practice. Retrieved from [EMA Website] (Actual URL would require specific search or access to EMA guidelines). [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Guidelines. Retrieved from [ICH Website] (Actual URL would require specific search or access to ICH guidelines). [4] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA Website] (Actual URL would require specific search or access to FDA guidance on DMFs). [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1998). ICH Q3A(R2): Impurities in New Drug Substances. [6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). [7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2007). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.